Geron Corp. and Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corp., have entered into an agreement for the manufacture of Geron’s GRNVAC1 telomerase vaccine. The agreement provides for the transfer of Geron’s vaccine production process to Cambrex and the cGMP manufacture of GRNVAC1 by Cambrex. Phase I/II trial of GRNVAC1 in metastatic prostate cancer patients showed that the vaccine was well tolerated with no major treatment-related toxicities. Also, Telomeras...